Testing for PDL-1 expression in NSCLC
Benjamin Philip Levy, MD, explains whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and what levels of PD-L1 expression are actionable
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio State University, Athens, OH, discusses the KEYNOTE-042 trial (NCT02220894), w...
Author: VJOncology
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
TRINITY: Rova-T for relapsed SCLC
Treatment options for small cell lung cancer (SCLC) have not advanced significantly in the past few decades, and patients with multiple relapses have no approved treatment options. In this video, reco...
Author: VJOncology
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Keynote trials from ASCO 2018 & the influence on choice of therapy
Joan Schiller, MD, talks about the Keynote trials presented and whether they will impact her choice of therapy for squamous or non-squamous lung cancer patients at the ASCO 2018 Annual Meeting.
Author: obr
Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Exciting new developments in lung cancer at ASCO 2018
David R. Gandara, MD, shares exciting new developments in lung cancer at ASCO 2018.
Author: obr
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Benefits of combination docetaxel + ramucirumab
Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell lung cancer (NSCLC) at ASCO 2018.
Author: obr
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy in common solid tumors: an overview
Much of the focus for immunotherapy research is on the cancers for which it works best, such as Hodgkin lymphoma and lung cancer. Elaine Vickers, BMedSc, PhD, from Science Communicated Ltd, Manchester...
Author: VJOncology
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Outcomes of Keynote 189 in metastatic NSCLC
Edgardo S. Santos, MD, FACP, talks about whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his view of PDL-1 expression and patient selection
Author: obr
Added: 07/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Edward B. Garon, MD, MS - Realizing the Potential of Precision Oncology in Lung Cancer —Challenges and Opportunities: Strengthening the Partnership Between Oncology and Pathology to Make the Most of the Latest Diagnostics and Therapies
Realizing the Potential of Precision Oncology in Lung Cancer—Challenges and Opportunities: Strengthening the Partnership Between Oncology and Pathology to Make the Most of the Latest Diagnostics and Therapies (Source: PeerView CME/CE Audio Podcast - Primary Care)
Source: PeerView CME/CE Audio Podcast - Primary Care - July 16, 2018 Category: Primary Care Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Lung cancer updates from UKOF 2018
Marianne Nicolson, MD, FRCP, BSc, MBChB, of NHS Grampian, Aberdeen, UK, gives an overview of a session discussing lung cancer that she chaired at the UK Oncology Forum (OF) 2018, held in Liverpool, UK...
Author: VJOncology
Added: 07/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 6, 2018 Category: Cancer & Oncology Source Type: podcasts
PEACE and TRACERx: dissecting metastases and intra-tumor heterogeneity
Mariam Jamal-Hanj, BSc, MBBS, PhD, of University College London, London, UK, discusses her talk regarding intra-tumor heterogeneity within lung cancer at the UK Oncology Forum (OF) 2018, held in Liver...
Author: VJOncology
Added: 07/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Lung cancer screening rates in the USA are too low
Lung cancer is the leading cause of cancer mortality in the United States, and low-dose CT scans are advised as a screening tool for high-risk groups such as smokers. In this video, recorded at the Am...
Author: VJOncology
Added: 07/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 4, 2018 Category: Cancer & Oncology Source Type: podcasts
New radiotherapy combinations
Gerry Hanna, MD, from Queens University Belfast, Belfast, UK, provides an insight into the two new landmark platforms investigating radiotherapy-drug combinations for non-small lung cancer (NSCLC). T...
Author: VJOncology
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Combination and monotherapies in NSCLC
An influx of novel therapies into the field of non-small cell lung cancer (NSCLC) has allowed healthcare professionals to utilize both combination and monotherapies in clinical practice. Speaking at t...
Author: VJOncology
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Guiding NSCLC treatment with biomarkers
The implementation of biomarkers into clinical practice is an exciting area of research, and the field of non-small cell lung cancer (NSCLC) is no exception to this. In this interview, Alastair Greyst...
Author: VJOncology
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
